Pharma Innovation 2019

October 25, 2019

Discover the latest tech and systems that have changed the game in pharmaceutical manufacturing

Spotlight

Drug Safety Research Unit

Our aim is to achieve the highest possible scientific and ethical standards, by putting the interests of patients first and to work with integrity and fairness with all our partners.

OTHER WHITEPAPERS
news image

Overcoming The Challenges of Pediatric Formulation

whitePaper | February 15, 2023

Pediatric populations represent the most diverse patient groups in all of medicine. Factors such as individual preferences, physiology, and dosage considerations all serve to complicate drug formulation aimed at pediatric care.

Read More
news image

BUILDING RESILIENT SUPPLY CHAINS REVITALIZING AMERICAN MANUFACTURING AND FOSTERING BROAD-BASED GROWTH

whitePaper | February 24, 2022

The COVID-19 pandemic and resulting economic dislocation revealed long-standing vulnerabilities in our supply chains. The pandemic’s drastic impacts on demand patterns for a range of medical products including essential medicines wreaked havoc on the U.S. healthcare system.

Read More
news image

A Comparison of Substance Use Disorders before and during theCOVID-19 Pandemic

whitePaper | September 22, 2022

During the COVID-19 pandemic, drug overdose deaths have increased. At the same time, access to and utilization of substance use disorder treatment services have decreased.

Read More
news image

Measuring the COVID Effect on Clinical Trials

whitePaper | June 27, 2022

As the world begins its transition into a postpandemic existence, it becomes possible to look back on the past two years and begin to quantify the effects that COVID-19 has brought.

Read More
news image

Research and Development in the Pharmaceutical Industry

whitePaper | April 1, 2021

Every year, the U.S. pharmaceutical industry develops a variety of new drugs that provide valuable medical benefits. Many of those drugs are expensive and contribute to rising health care costs for the private sector and the federal government. Policymakers have considered policies that would lower drug prices and reduce federal drug expenditures. Such policies would probably reduce the industry’s incentive to develop new drugs.

Read More
news image

Asia Pacific as a Clinical Trials Powerhouse

whitePaper | October 6, 2022

Patient availability is a critical component for clinical trials, and so it stands to reason that clinical development should match the epidemiology of diseases. Of course, this is often not the case,

Read More

Spotlight

Drug Safety Research Unit

Our aim is to achieve the highest possible scientific and ethical standards, by putting the interests of patients first and to work with integrity and fairness with all our partners.

Events